ArticleOncology letters2019

Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.

Jie Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.